Current drug therapy for heart failure with reduced ejection fraction

Area of Science:

• Cardiology
• Pharmacology

Background:

• Heart failure prevalence is rising globally, posing a significant health challenge.
• Untreated heart failure has a poor prognosis, necessitating effective therapeutic strategies.

Purpose of the Study:

• To review recent advances in pharmacotherapy for heart failure with reduced ejection fraction (HFrEF).
• To highlight emerging treatments and their potential impact on HFrEF patient outcomes.

Main Methods:

• Review of current guideline-recommended drug therapies for HFrEF.
• Discussion of novel therapeutic agents, including angiotensin receptor-neprilysin inhibitors and potassium binders.
• Consideration of ongoing research, such as trials on cardiac glycosides.

Main Results:

• Standard therapies including ACE inhibitors (ACEi), beta-blockers, and diuretics have improved HFrEF prognosis.
• Adequate dosing of ACEi and beta-blockers remains critical.
• New agents like angiotensin receptor-neprilysin inhibitors show promise for future treatment paradigms.
• Potassium binders may help manage hyperkalemia, a common limitation in HFrEF drug dosing.

Conclusions:

• Significant progress has been made in HFrEF management through guideline-directed medical therapy.
• Emerging treatments offer hope for enhanced prognosis and quality of life for HFrEF patients.
• Personalized approaches, including managing drug interactions and side effects, are key to optimizing HFrEF care.